10x Genomics, Inc. (NASDAQ:TXG) Director Alan Mateo Buys 40,000 Shares

10x Genomics, Inc. (NASDAQ:TXG) Director Alan Mateo bought 40,000 shares of the firm’s stock in a transaction on Friday, February 21st. The stock was purchased at an average cost of $11.14 per share, for a total transaction of $445,600.00. Following the completion of the acquisition, the director now owns 61,691 shares in the company, valued at approximately $687,237.74. This trade represents a 184.41 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

10x Genomics Price Performance

NASDAQ:TXG opened at $11.11 on Wednesday. The firm’s 50 day simple moving average is $14.16 and its 200 day simple moving average is $16.95. 10x Genomics, Inc. has a one year low of $10.63 and a one year high of $48.42. The company has a market cap of $1.36 billion, a PE ratio of -7.31 and a beta of 1.85.

10x Genomics (NASDAQ:TXG) last posted its earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. Equities research analysts expect that 10x Genomics, Inc. will post -1.43 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Stifel Nicolaus decreased their target price on shares of 10x Genomics from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of 10x Genomics in a report on Wednesday, February 19th. Canaccord Genuity Group decreased their target price on shares of 10x Genomics from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Morgan Stanley reduced their price target on shares of 10x Genomics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Finally, JPMorgan Chase & Co. reduced their price target on shares of 10x Genomics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, 10x Genomics has an average rating of “Hold” and an average price target of $20.57.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of TXG. Signaturefd LLC lifted its position in shares of 10x Genomics by 424.6% in the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock worth $26,000 after purchasing an additional 1,452 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of 10x Genomics in the 4th quarter worth approximately $32,000. Capital Performance Advisors LLP acquired a new position in shares of 10x Genomics in the 3rd quarter worth approximately $35,000. Blue Trust Inc. lifted its position in shares of 10x Genomics by 136.5% in the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock worth $40,000 after purchasing an additional 1,025 shares during the period. Finally, Sound Income Strategies LLC lifted its position in shares of 10x Genomics by 65.2% in the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock worth $48,000 after purchasing an additional 1,330 shares during the period. Institutional investors and hedge funds own 84.68% of the company’s stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.